2018
Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems.
Verplaetse TL, McKee SA, Petrakis IL. Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems. Alcohol Research 2018, 39: 193-205. PMID: 31198658, PMCID: PMC6561397.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderCo-occurring alcohol use disorderAlcohol use disorderComorbid alcohol use disorderStress disorderNeurobiological systemsMaintenance of AUDUse disordersPTSD symptom severityAlcohol-motivated behaviorsAlcohol use outcomesPharmacologic treatment strategiesBrain systemsTreatment of individualsCurrent medicationsComorbid populationGlutamatergic systemPotential pharmacotherapyPharmacologic interventionsUse outcomesTreatment outcomesTreatment strategiesSingular diagnosisDual diagnosisTreatment interventions
2016
Targeting the Brain Stress Systems for the Treatment of Tobacco/Nicotine Dependence: Translating Preclinical and Clinical Findings
Verplaetse TL, McKee SA. Targeting the Brain Stress Systems for the Treatment of Tobacco/Nicotine Dependence: Translating Preclinical and Clinical Findings. Current Addiction Reports 2016, 3: 314-322. PMID: 31275802, PMCID: PMC6609087, DOI: 10.1007/s40429-016-0115-x.Peer-Reviewed Original ResearchBrain stress systemsTobacco useNoradrenergic systemTreatment strategiesCorticotropin-releasing factor (CRF) systemTobacco/nicotine dependenceMajority of smokersNicotine-induced activationPotential treatment strategySmoking-related outcomesNicotine-motivated behaviorsLong-term abstinenceStress systemClinical findingsAdrenal axisTobacco dependencePreventable mortalityClinical investigationNicotine dependenceRecent FindingsOneTherapeutic benefitPharmacological agentsCRF systemDrug AdministrationSummaryThis review
2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomen